Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.

Cancer chemotherapy and pharmacology - 1 Apr 2016

Tamura Kenji, Hashimoto Jun, Tanabe Yuko, Kodaira Makoto, Yonemori Kan, Seto Takashi, Hirai Fumihiko, Arita Shuji, Toyokawa Gouji, Chen Lan, Yamamoto Hiroshi, Kawata Toshio, Lindemann Justin, Esaki Taito

Abstract excerpt

PURPOSE: Investigate the safety and tolerability of AZD5363 and define a recommended dose for evaluation in Japanese patients with advanced solid malignancies. METHODS: AZD5363 was administered orally as a single dose, and then the dose was escalated to twice daily (bid) in separate continuous (every day) and intermittent (4 days on, 3 days off [4/3] or 2 days on, 5 days off [2/5]) dosing schedules to reach...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Proto-Oncogene Proteins c-akt

Share to Pyrimidines

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 26931343
DOI: 10.1007/s00280-016-2987-9
PMCID: PMC4819940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.PMID 26931343Read ↗

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.Semantic proximity Read ↗

First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.Semantic proximity Read ↗

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

663P First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumorsSemantic proximity Read ↗

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.Semantic proximity Read ↗

Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of CancersSemantic proximity Read ↗

A phase II Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN -Inactivating MutationsSemantic proximity Read ↗

CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.Semantic proximity Read ↗

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.Semantic proximity Read ↗

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b StudySemantic proximity Read ↗

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.Semantic proximity Read ↗

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.